Table 1.

Various action pathways of dimebolin affecting memory

Pathway	Dose/concentration of dimebolin used	Study
Mechanism involving H1 blockade	Data not available	Mateeva et al. 1983
Inhibitory effect on the deamination in basal ganglia and hypothalamus	100 μM in vitro	Shadurskaia et al. 1986
Inhibits neurotoxin (AF64A)‐ induced neurodegeneration	1mg/kg body weight injected intraperitoneally	Lermontova et al. 2000
Protected cerebellar neurons against the action of β‐amyloid, anticholinestrase activity, NMDA blocking activity, inhibition of potential‐dependent Ca2+ uptake	25 μM concentration in cultured neurons; IC50 = 57 μM for effect on Ca2+ uptake; IC50 = 7.9 μM; and 42 μM for butyrylcholine esterase and acetylcholine esterase, respectively; NMDA blocking activity at EC50 = 42 ± 6 mg/kg intraperitoneal	Bachurin et al. 2001 Lermontova et al. 2001
Optimizing mitochondrial pore dysfunction	200 μM	Bachurin et al. 2003
NMDA receptor antagonist at high concentrations, and at low dose acts as positive modulator of AMPA receptors	Above 6 μM, blocked NMDA‐ induced currents, above 0.2 μM for AMPA‐modulating effect	Grigorev et al. 2003
NMDA blocking and protective effects against glutamate‐induced apoptosis	IC 50 = 10 μM for NMDA blocking effects; and higher concentration of 50 μM for protection against glutamate‐induced	Wu et al. 2008
Activity on 5‐HT6 receptors may affect short‐term memory	K(i) = 26.0+/−2.5nM (IC50 = 0.89 μM)	Schaffhauser et al. 2009, Ivachtchenko et al. 2009
Increased expression of β‐amyloid excretion	Intraperitoneal injection 3.5 mg/kg, Extracellular concentration of 1–10 μM	Cirrito et al. 2009; Gandy et al. 2009
Inhibitory effect on TDP‐43 (TAR DNA binding) protein aggregation in thrice‐cloned neuroblastoma cells	5 μM	Yamashita et al. 2009